@article{4622b832f42f4f079c474215a71b367c,
title = "Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents",
abstract = "A series of tetracyclic heterocyclic azathioxanthones were synthesized and evaluated for cell proliferations, topoisomerase inhibitions, and NCI-60 cell panel assay, respectively. Compounds 5, 7, 8, 16, and 19 were selected for topoisomerase assay after MTT assay. 7 not only showed cytotoxic effect (IC50 Combining double low line 2.84 ± 0.64 μM) in PC-3 cells but also revealed topoisomerases inhibition with IC50 (10-25 μM) and increased apoptotic cleavage of PARP and caspase 3 activity. The overall of novel azathioxanthones with different cytostatic and cytotoxic activities should be further developed as new potential candidates for anticancer drugs.",
keywords = "Azathioxanthones, Cytostatic and cytotoxic activities, MTT assay, NCI-60 human tumor cell lines, Topoisomerase assays",
author = "Chen, {Tsung Chih} and Wu, {Chia Lun} and Lee, {Chia Chung} and Chen, {Chun Liang} and Yu, {Dah Shyong} and Huang, {Hsu Shan}",
note = "Funding Information: We are appreciatory to Dr. Daniel Steve Villarreal, Ph.D. for revising the grammar and spelling in this paper. Sincerely, the authors also thank the NCI Developmental Therapeutics Program (DTP) for 60 cancer cell line screen of selected compounds described in this paper funded by National Cancer Institute , National Institutes of Health (NIH-NCI). The present study was support by National Science Council Grants of Taiwan ( NSC101-2113-M-016 and NSC101-2314-B-016-005 ), Ministry of Science and Technology Grants of Taiwan ( MOST103-2113-M-038-002 ), Chi-Mei Medical Center ( CMNDMC-10210 ) and National Defense Medical Center ( NDMC-103-MAB-81 ). Funding Information: We are appreciatory to Dr. Daniel Steve Villarreal, Ph.D. for revising the grammar and spelling in this paper. Sincerely, the authors also thank the NCI Developmental Therapeutics Program (DTP) for 60 cancer cell line screen of selected compounds described in this paper funded by National Cancer Institute, National Institutes of Health (NIH-NCI). The present study was support by National Science Council Grants of Taiwan (NSC101-2113- M-016 and NSC101-2314-B-016-005), Ministry of Science and Technology Grants of Taiwan (MOST103-2113-M-038-002), Chi- Mei Medical Center (CMNDMC-10210) and National Defense Medical Center (NDMC-103-MAB-81). Publisher Copyright: {\textcopyright} 2015 Elsevier Masson SAS. All rights reserved.",
year = "2015",
month = oct,
day = "20",
doi = "10.1016/j.ejmech.2014.09.050",
language = "English",
volume = "103",
pages = "615--627",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",
}